SEC Form 4 · accession 0001209191-16-100020
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank H Valone M.D.
Officer — Chief Medical Officer
Period of report
Feb 16, 2016
Accepted (ET)
Feb 18, 2016 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 16, 2016 | M | 2,492 | $2.90 | A | 99,332 | D | |
| Common Stock | Feb 16, 2016 | M | 8,258 | $3.50 | A | 107,590 | D | |
| Common StockF1,F2 | Feb 16, 2016 | S | 10,750 | $18.4133 | D | 96,840 | D | |
| Common Stock | holding | — | — | — | 4,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $2.90 | Feb 16, 2016 | M | 2,492 | D | — | Jun 9, 2020 | Common Stock | 2,492 | 7,508 | D |
| Stock Option (Right to Buy)F4 | $3.50 | Feb 16, 2016 | M | 8,258 | D | — | Jun 7, 2021 | Common Stock | 8,258 | 31,742 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices between $18.0122 and $18.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Twenty percent of the shares subject to each option vests on the first anniversary of the vesting commencement date and 80% of the shares subject to each option vests in 16 substantially equal quarterly installments thereafter over for the following four years.
- F4Fully vested.